The U.S. FDA has approved Rasonque (daraxonrasib), a new targeted therapy for adults with metastatic pancreatic adenocarcinoma. In a 500-patient clinical trial, the treatment more than doubled median overall survival compared with standard chemotherapy, marking a significant development in pancreatic cancer care.
